Back to the main directory
Company Analysis / Equity
- VNRX: Launch Still Expected in 2016. Pancreatic Cancer Expected to Be 2nd Indication by Zacks
- VNRX: Positive Clinical Data Continues To Support Our Buy Thesis. Shares Still Have ~50% Upside. by Zacks
- VNRX: Readout of Retro & Prosp Studies Upcoming, Add l Info on Europe / U.S. Strategies by Zacks
- VNRX: Strongly Priced Stock Sale. Maintaining Outperform Rating by Zacks
- VNRX: Upcoming Interim Trial Data Could Push Share Price Even Higher by Zacks
- Zacks Company Report by Zacks
- APHB: Safety of AB-SA01 Firmly Established Following Phase 1 Trials by Zacks
- High Quality 10,800 Sample Base Could Catalyze CE Mark Submission by Zacks
- VNRX: Clinical Data Looks Promising For Colon Cancer Opportunity by Zacks
- VNRX: Initial 1,000-Patient Data From Colon Cancer Study Should Be Forthcoming & Could Be Catalyst to Share Price by Zacks
- Q2 10-Q Filed. Maintaining Buy Rec, $7.25 Price Target by Zacks
- APHB: Results from Two Phase 1 Studies of AB-SA01 to be Reported in 2H16… by Zacks
- APHB: AB-SA01 Phase 1 Trial Underway by Zacks
- APHB: AmpliPhi Converts All Outstanding Series B Preferred Stock by Zacks
- APHB: Development of bacteriophage therapies continues by Zacks
- APHB: Initiating coverage of APHB, developer of bacteriophage therapies by Zacks
- APHB: Preclinical Data Shows Broad Activity of AB-PA01 Against P. Aeruginosa Clinical Isolates; ECC With Intrexon Canceled… by Zacks
- AYTU: Initiation Report by Zacks
- AYTU: Reports Q1 2017 Financial Results; Revenue Improves 42% Quarter-Over- Quarter! by Zacks
- BPMX: A specialty pharma company with a focus on women s health and dermatology initiating with Buy rating by Zacks
- BPMX: Phase IV of VI2LET initiated, data expected by the end of 2016; Phase IIa of BPX01 for acne completed enrollment, data expected in mid-2016. by Zacks
- BPMX: Progress made in both commercial product and clinical programs Buy by Zacks
- CPKF: CPKF Has Another Good Quarter by Zacks
- CPKF: Larger-Than- Expected Loan Growth, Loan Loss Provision, and Net Charge-offs Highlight the Second Quarter by Zacks
- CPKF: Reducing 2016 EPS Estimate by a Nickel, but Maintaining 2017 EPS Estimate by Zacks